BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Alios BioPharma Issued Broad U.S. Patent for Glyco-Engineered Interferons


10/16/2009 8:39:33 AM

SOUTH SAN FRANCISCO, CA--(Marketwire - October 16, 2009) - Alios BioPharma, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,597,884, claiming numerous compounds from the company's glycoengineering program including its IND candidate, Glycoferon™, which is being developed for the treatment of chronic hepatitis C. The patent, titled "Hyperglycosylated Polypeptide Variants and Methods of Use" and issued on October 6, 2009, is the first patent granted to Alios BioPharma for the company's proprietary approach for glycoengineering of proteins including type 1 interferons.

"This patent represents a significant milestone for Alios as the method for glycoprotein-engineering of interferons is being applied to the development of an interferon alpha (Glycoferon™) molecule, which may be useful for the treatment of chronic hepatitis C, and an interferon beta (Beta-Gly™) molecule, which may be useful for the treatment of relapsing remitting multiple sclerosis. Both of these compounds have the potential for once monthly dosing without compromising biological potency," commented Leonid M. Beigelman, Ph.D., Executive Vice President, Research of Alios BioPharma, Inc.

Less frequent dosing of a treatment for chronic diseases such as hepatitis C and relapsing remitting multiple sclerosis has many potential benefits, including the possibility for increased patient compliance potentially leading to better tolerability and increased efficacy.

The company will present its preclinical results for the Glycoferon program, including efficacy in a yellow fever virus model (a surrogate model for chronic hepatitis C), at the American Association for the Study of Liver Diseases (AASLD) conference to be held October 30 through November 3 in Boston. The poster, "Significant improvement of the pharmacokinetic profile of a hyper-glycosylated consensus type 1 interferon," will be presented on November 3rd between 8 am and 1 pm by Alios senior scientist Jin Hong, Ph.D.

About Alios BioPharma

Alios BioPharma, Inc., an emerging biotechnology company headquartered in South San Francisco, California, is developing novel medicines to treat viral diseases by activating pathways in the innate immune system. Alios is developing small-molecule and protein therapeutics addressing major market opportunities.


Contacts:
Debra Bannister (media)
Communications Consultant
530 676-8001

Alios BioPharma
Bruce Bryan
MBA (corporate)
Senior Director of Operations and Project Management
650 635-5502
press@aliosbiopharma.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->